ArticleInternational journal of retina and vitreous2026
Prevention of postoperative proliferative vitreoretinopathy in complex retinal detachments with serial intravitreal methotrexate injections.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nomogram-based prediction of postoperative proliferative vitreoretinopathy following scleral buckling surgery for rhegmatogenous retinal detachment.International journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProliferative vitreoretinopathy (PVR) remains the leading cause of surgical failure after rhegmatogenous retinal detachment (RRD) repair. Intravitreal methotrexate (MTX) has emerged as a potential antiproliferative adjunct; however, the available evidence remains inconclusive. This study evaluated the safety and clinical outcomes associated with a standardized protocol of serial intravitreal MTX injections administered throughout the critical postoperative period in eyes with complex RRD.
methodsThis retrospective observational analysis included 49 eyes of 49 patients selected from 50 consecutively screened patients undergoing pars plana vitrectomy (PPV) for complex RRD, defined as PVR grade C, recurrent retinal detachment due to PVR, or retinal detachment associated with penetrating ocular trauma. All included eyes were treated according to a standardized institutional protocol consisting of an intraoperative intravitreal MTX injection (400 µg/0.1 mL), followed by biweekly injections through postoperative week 12. The primary outcome was single-surgery anatomic success (SSAS), defined as retinal reattachment without fibrotic membrane formation at 12 weeks. Secondary outcomes included final retinal reattachment over total follow-up, changes in best-corrected visual acuity (BCVA), and safety outcomes.
resultsForty-nine of 50 screened patients met the inclusion criteria and were included in the final analysis. SSAS at 12 weeks was achieved in 42 of 49 eyes (85.7%). Seven eyes required reoperation during follow-up, yielding a final retinal reattachment rate of 93.8% over the total follow-up period. Mean BCVA improved significantly from 2.52 ± 0.58 logMAR preoperatively to 1.23 ± 0.84 logMAR at 3 months (p < 0.001). Mean follow-up was 14.7 ± 10.8 months. The most frequent adverse event among analyzed eyes was conjunctival hyperemia, which resolved after completion of the MTX protocol. No severe ocular or systemic MTX-related adverse events were observed.
conclusionsSerial intravitreal MTX administered during the early postoperative period showed a favorable safety profile and was associated with encouraging anatomic and visual outcomes in this cohort of complex RRD. However, given the retrospective design, lack of a control group, cohort heterogeneity, potential selection bias, and the influence of adjunctive surgical procedures, these findings should be interpreted cautiously and as hypothesis-generating. Prospective controlled studies are required to better define the role of MTX in preventing postoperative PVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.